nm21-1480

NM21‑1480 is a next-generation, tri-specific antibody fragment designed for cancer immunotherapy. It simultaneously targets and blocks the immune-suppressive PD‑L1 pathway, agonizes the T cell co-stimulatory receptor 4‑1BB (CD137), and binds human serum albumin (HSA) to extend half-life. Its unique mechanism restricts 4‑1BB activation to the tumor microenvironment by requiring simultaneous engagement of both PD‑L1 and 4‑1BB, thereby aiming to maximize anti-tumor immune responses while minimizing systemic toxicity. NM21‑1480 has demonstrated potent biological activity in preclinical models and early clinical trials, with evidence of disease control in patients with advanced solid tumors—including those resistant to prior immunotherapies. The drug is being developed as both monotherapy and in combination regimens for various solid tumors[1][2][3][4][5][6].

Other names

4-1BB/PD-L1/HSA trispecific MATCH3 antibodyAnti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific AntibodyPD-L1/4-1BB/HSA trispecific scDb-scFvTrispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin single-chain Fv fusion protein